Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver

Human UDP-glucuronosyltransferases: Feedback loops between substrates and ligands of their transcription factors

(2012) Karl Walter Bock   BIOCHEMICAL PHARMACOLOGY

UGT2B17 Genetic Polymorphisms Dramatically Affect the Pharmacokinetics of MK-7246 in Healthy Subjects in a First-in-Human Study

(2012) Y-H Wang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Function, Genetic Polymorphism, and Transcriptional Regulation of Human UDP-glucuronosyltransferase (UGT) 1A1

(2012) Junko Sugatani   Drug Metabolism and Pharmacokinetics

Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer

(2012) Wei Tang et al.   HUMAN MOLECULAR GENETICS

An integrated map of genetic variation from 1,092 human genomes

(2012)   NATURE

A signature of balancing selection in the region upstream to the human UGT2B4 gene and implications for breast cancer risk

(2011) Chang Sun et al.   HUMAN GENETICS

HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants

(2011) L. D. Ward et al.   NUCLEIC ACIDS RESEARCH

Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab

(2011) Janet S. Lee et al.   Pharmacogenetics and Genomics

In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole

(2010) Landry K. Kamdem et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Alternatively Spliced Products of the UGT1A Gene Interact with the Enzymatically Active Proteins to Inhibit Glucuronosyltransferase Activity In Vitro

(2010) J. Bellemare et al.   DRUG METABOLISM AND DISPOSITION

A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci

(2010) Nathaniel Rothman et al.   NATURE GENETICS

A pharmacogenetic study of vorinostat glucuronidation

(2010) Soonmo Peter Kang et al.   Pharmacogenetics and Genomics

Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics

(2010) Dongxiao Sun et al.   Pharmacogenetics and Genomics

Pharmacogenetics and pharmacogenomics of anticancer agents

(2009) R. S. Huang et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Characterization of UGTs Active against SAHA and Association between SAHA Glucuronidation Activity Phenotype with UGT Genotype

(2009) R. M. Balliet et al.   CANCER RESEARCH

Genetic Polymorphisms in the TATA Box and Upstream Phenobarbital-Responsive Enhancer Module of the UGT1A1 Promoter Have Combined Effects on UDP-Glucuronosyltransferase 1A1 Transcription Mediated by Constitutive Androstane Receptor, Pregnane X Receptor, or Glucocorticoid Receptor in Human Liver

(2009) Y. Li et al.   DRUG METABOLISM AND DISPOSITION

UGT genomic diversity: beyond gene duplication

(2009) Chantal Guillemette et al.   DRUG METABOLISM REVIEWS

Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease

(2009) Steven A McCarroll et al.   NATURE GENETICS

Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene

(2009) Federico Innocenti et al.   Pharmacogenetics and Genomics

Genome-wide Copy-Number-Variation Study Identified a Susceptibility Gene, UGT2B17, for Osteoporosis

(2008) Tie-Lin Yang et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Metabolism and Renal Elimination of Gaboxadol in Humans: Role of UDP-Glucuronosyltransferases and Transporters

(2008) Xiao-Yan Chu et al.   PHARMACEUTICAL RESEARCH